Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 Biomarker disease BEFREE Herein, we will review the clinically relevant inhibitors of the PI3K pathway that have been evaluated or hold promise for the treatment of Ph-ve MPNs. 26062813 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 AlteredExpression disease BEFREE Molecular profiling of CD34+ cells and granulocytes of MPN determined gene expression patterns beyond their recognized function in disease pathogenesis that included dominant up-regulation of PI3K/AKT signaling. 26275051 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 Biomarker disease BEFREE In conclusion, combined inhibition of PI3K/mTOR and JAK2 signalling may represent a novel therapeutic strategy in MPN. 24237791 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 Biomarker disease BEFREE Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs. 24251790 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 Biomarker disease BEFREE Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. 22806893 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.060 Biomarker disease BEFREE Many drugs are now under investigations targeting different pathways critical for MPN development, such as the JAK-STAT (JAK2 inhibitors: INCB018424 or ruxolitinib, TG101348 or SAR302503, CYT387, SB1518, CEP701 and LY2784544) and the PI3K/AKT/mTOR (everolimus) pathways, or act through remodeling of chromatin with a key role in epigenetics (givinostat, panobinostat and vorinostat). 22227528 2012